

# Paolo Blasi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6483707/publications.pdf>

Version: 2024-02-01

74  
papers

3,800  
citations

136740  
32  
h-index

123241  
61  
g-index

80  
all docs

80  
docs citations

80  
times ranked

5647  
citing authors

#	ARTICLE	IF	CITATIONS
1	Natural-like Chalcones with Antitumor Activity on Human MG63 Osteosarcoma Cells. <i>Molecules</i> , 2022, 27, 3751.	1.7	1
2	Nanospermidine in Combination with Nanofenretinide Induces Cell Death in Neuroblastoma Cell Lines. <i>Pharmaceutics</i> , 2022, 14, 1215.	2.0	7
3	Amelogenin-Derived Peptides in Bone Regeneration: A Systematic Review. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9224.	1.8	7
4	Tablet Splitting in Elderly Patients with Dementia: The Case of Quetiapine. <i>Pharmaceutics</i> , 2021, 13, 1523.	2.0	6
5	Surfactant Self-Assembling and Critical Micelle Concentration: One Approach Fits All?. <i>Langmuir</i> , 2020, 36, 5745-5753.	1.6	100
6	The COPHELA (Cooperation in Quality Assurance for Pharmacy Education and Training between Europe) Tj ETQq0 0.0 rgBT /Qverlock 10	0.6	0
7	Ketoprofen poly(lactide-co-glycolide) physical interaction studied by Brillouin spectroscopy and molecular dynamics simulations. <i>International Journal of Pharmaceutics</i> , 2020, 580, 119235.	2.6	6
8	Poly(lactic acid)/poly(lactic-co-glycolic acid)-based microparticles: an overview. <i>Journal of Pharmaceutical Investigation</i> , 2019, 49, 337-346.	2.7	147
9	Dynamics of Clay-Intercalated Ibuprofen Studied by Solid State Nuclear Magnetic Resonance. <i>Molecular Pharmaceutics</i> , 2019, 16, 2569-2578.	2.3	10
10	Tumor Targeting by Peptide-Decorated Gold Nanoparticles. <i>Molecular Pharmaceutics</i> , 2019, 16, 2430-2444.	2.3	37
11	Poly(lactic acid)/poly(lactic-co-glycolic acid)-based microparticles: an overview. , 2019, 49, 337.		1
12	Biodegradable composite porous poly(<sc>dl</sc>-lactide-<i>co</i>-glycolide) scaffold supports mesenchymal stem cell differentiation and calcium phosphate deposition. <i>Artificial Cells, Nanomedicine and Biotechnology</i> , 2018, 46, 219-229.	1.9	17
13	Differentiation of Ecuadorian National and CCNâ€51 cocoa beans and their mixtures by computer vision. <i>Journal of the Science of Food and Agriculture</i> , 2018, 98, 2824-2829.	1.7	15
14	Artificial apolipoprotein corona enables nanoparticle brain targeting. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2018, 14, 429-438.	1.7	63
15	Potentially Inappropriate Prescribing of Oral Solid Medications in Elderly Dysphagic Patients. <i>Pharmaceutics</i> , 2018, 10, 280.	2.0	14
16	Injectable nanoemulsions prepared by high pressure homogenization: processing, sterilization, and size evolution. <i>Applied Nanoscience (Switzerland)</i> , 2018, 8, 1483-1491.	1.6	19
17	Innovative Nanoparticles Enhance N-Palmitoylethanolamide Intraocular Delivery. <i>Frontiers in Pharmacology</i> , 2018, 9, 285.	1.6	35
18	Oral drug therapy in elderly with dysphagia: between a rock and a hard place!. <i>Clinical Interventions in Aging</i> , 2017, Volume 12, 241-251.	1.3	68

#	ARTICLE	IF	CITATIONS
19	Chitosan-pectin hybrid nanoparticles prepared by coating and blending techniques. European Journal of Pharmaceutical Sciences, 2016, 84, 37-45.	1.9	68
20	Nanoparticles prolong N-palmitoylethanolamide anti-inflammatory and analgesic effects in vivo. Colloids and Surfaces B: Biointerfaces, 2016, 141, 311-317.	2.5	23
21	Acoustic spectroscopy: A powerful analytical method for the pharmaceutical field?. International Journal of Pharmaceutics, 2016, 503, 174-195.	2.6	34
22	Are tyrosinase inhibitors in sunscreens and cosmetics enhancing <scp>UV</scp> carcinogenicity?. Experimental Dermatology, 2015, 24, 546-547.	1.4	9
23	Dynamic behavior of a spring-powered micronozzle needle-free injector. International Journal of Pharmaceutics, 2015, 491, 91-98.	2.6	34
24	Effect of Fermentation and Drying on Cocoa Polyphenols. Journal of Agricultural and Food Chemistry, 2015, 63, 9948-9953.	2.4	57
25	In vitro and in vivo toxicity evaluation of plant virus nanocarriers. Colloids and Surfaces B: Biointerfaces, 2015, 129, 130-136.	2.5	25
26	Powder, capsule and device: An imperative mÃ©nage Ã trois for respirable dry powders. International Journal of Pharmaceutics, 2015, 494, 40-48.	2.6	18
27	Î²-cyclodextrin hinders PLGA plasticization during microparticle manufacturing. Journal of Drug Delivery Science and Technology, 2015, 30, 375-383.	1.4	10
28	Alginates in Pharmaceuticals and Biomedicine: Is the Future so Bright?. Current Pharmaceutical Design, 2015, 21, 4917-4935.	0.9	26
29	Ketoprofen enantioseparation with a Cinchona alkaloid based stationary phase: Enantiorecognition mechanism and release studies. Journal of Separation Science, 2014, 37, 2696-2703.	1.3	18
30	The Influence of Feedstock and Process Variables on the Encapsulation of Drug Suspensions by Sprayâ€Drying in Fast Drying Regime: The Case of Novel Antitubercular Drugâ€Palladium Complex Containing Polymeric Microparticles. Journal of Pharmaceutical Sciences, 2014, 103, 1255-1268.	1.6	18
31	Capreomycin inhalable powders prepared with an innovative spray-drying technique. International Journal of Pharmaceutics, 2014, 469, 132-139.	2.6	31
32	Chitosan nanoparticles: Preparation, size evolution and stability. International Journal of Pharmaceutics, 2013, 455, 219-228.	2.6	460
33	Development of a spray-drying method for the formulation of respirable microparticles containing ofloxacinâ€palladium complex. International Journal of Pharmaceutics, 2013, 440, 273-282.	2.6	58
34	Capreomycin supergenerics for pulmonary tuberculosis treatment: Preparation, in vitro, and in vivo characterization. European Journal of Pharmaceutics and Biopharmaceutics, 2013, 83, 388-395.	2.0	43
35	Conformal polymer coatings for pancreatic islets transplantation. International Journal of Pharmaceutics, 2013, 440, 141-147.	2.6	16
36	Lipid nanoparticles for brain targeting III. Long-term stability and in vivo toxicity. International Journal of Pharmaceutics, 2013, 454, 316-323.	2.6	45

#	ARTICLE	IF	CITATIONS
37	Lipid nanoparticles for brain targeting II. Technological characterization. Colloids and Surfaces B: Biointerfaces, 2013, 110, 130-137.	2.5	32
38	Evaluation of <i>In Vitro</i> Cytotoxicity and Genotoxicity of Size-Fractionated Air Particles Sampled during Road Tunnel Construction. BioMed Research International, 2013, 2013, 1-9.	0.9	7
39	Synthesis, characterization and <i>in vitro</i> extracellular and intracellular activity against <i>Mycobacterium tuberculosis</i> infection of new second-line antitubercular drug-palladium complexes. Journal of Pharmacy and Pharmacology, 2013, 66, 106-121.	1.2	19
40	Microencapsulation of Bioactive Principles with an Airless Spray-Gun Suitable for Processing High Viscous Solutions. Journal of Functional Biomaterials, 2013, 4, 312-328.	1.8	2
41	Nanoparticles in Biomedicine: New Insights from Plant Viruses. Current Medicinal Chemistry, 2013, 20, 3471-3487.	1.2	27
42	Accelerated Polymer Biodegradation of Risperidone Poly(d, L-Lactide-Co-Glycolide) Microspheres. AAPS PharmSciTech, 2012, 13, 1465-1472.	1.5	42
43	Response to Comment on Blasi et al. (2011) "Lipid nanoparticles for brain targeting I. Formulation optimization" International Journal of Pharmaceutics, 2012, 439, 171-174.	2.6	0
44	Lipid Nanoparticles as Carrier for Octyl-Methoxycinnamate: In Vitro Percutaneous Absorption and Photostability Studies. Journal of Pharmaceutical Sciences, 2012, 101, 301-311.	1.6	49
45	Effect of Agitation Regimen on the in vitro Release of Leuprolide from Poly(Lactic-Co-Glycolic) Acid Microparticles. Journal of Pharmaceutical Sciences, 2012, 101, 1212-1220.	1.6	10
46	Lipid nanoparticles for brain targeting I. Formulation optimization. International Journal of Pharmaceutics, 2011, 419, 287-295.	2.6	48
47	The functional performance of microencapsulated human pancreatic islet-derived precursor cells. Biomaterials, 2011, 32, 9254-9262.	5.7	26
48	The real value of novel particulate carriers for sunscreen formulation. Expert Review of Dermatology, 2011, 6, 509-517.	0.3	16
49	Bioactive Long-Term Release from Biodegradable Microspheres Preserves Implanted ALG-PLO-ALG Microcapsules from In Vivo Response to Purified Alginate. Pharmaceutical Research, 2010, 27, 285-295.	1.7	13
50	Simple and scalable method for peptide inhalable powder production. European Journal of Pharmaceutical Sciences, 2010, 39, 53-58.	1.9	25
51	Development of a scalable procedure for fine calcium alginate particle preparation. Chemical Engineering Journal, 2010, 160, 363-369.	6.6	54
52	Lipid Nanoparticles for Drug Delivery to the Brain: <i>In Vivo</i> Veritas. Journal of Biomedical Nanotechnology, 2009, 5, 344-350.	0.5	16
53	Novel composite microparticles for protein stabilization and delivery. European Journal of Pharmaceutical Sciences, 2009, 36, 226-234.	1.9	54
54	Fighting tuberculosis: old drugs, new formulations. Expert Opinion on Drug Delivery, 2009, 6, 977-993.	2.4	38

#	ARTICLE	IF	CITATIONS
55	Physicochemical characterization and release mechanism of a novel prednisone biodegradable microsphere formulation. <i>Journal of Pharmaceutical Sciences</i> , 2008, 97, 303-317.	1.6	28
56	Lipid nanoparticles for prolonged topical delivery: An in vitro and in vivo investigation. <i>International Journal of Pharmaceutics</i> , 2008, 357, 295-304.	2.6	229
57	Influence of Compression Force on The Behavior of Mucoadhesive Buccal Tablets. <i>AAPS PharmSciTech</i> , 2008, 9, 274-281.	1.5	20
58	Preparation of large porous biodegradable microspheres by using a simple double-emulsion method for capreomycin sulfate pulmonary delivery. <i>International Journal of Pharmaceutics</i> , 2007, 333, 103-111.	2.6	69
59	Solid lipid nanoparticles for targeted brain drug delivery†. <i>Advanced Drug Delivery Reviews</i> , 2007, 59, 454-477.	6.6	432
60	Ketoprofen poly(lactide-co-glycolide) physical interaction. <i>AAPS PharmSciTech</i> , 2007, 8, E78-E85.	1.5	76
61	Mucoadhesive bilayered tablets for buccal sustained release of flurbiprofen. <i>AAPS PharmSciTech</i> , 2007, 8, E20-E27.	1.5	45
62	Development of liposomal capreomycin sulfate formulations: Effects of formulation variables on peptide encapsulation. <i>International Journal of Pharmaceutics</i> , 2006, 311, 172-181.	2.6	52
63	Preparation and in vitro and in vivo characterization of composite microcapsules for cell encapsulation. <i>International Journal of Pharmaceutics</i> , 2006, 324, 27-36.	2.6	31
64	Evaluation of alternative strategies to optimize ketorolac transdermal delivery. <i>AAPS PharmSciTech</i> , 2006, 7, E61-E69.	1.5	76
65	Evaluation and Optimization of the Conditions for an Improved Ferulic Acid Intercalation into a Synthetic Lamellar Anionic Clay. <i>Pharmaceutical Research</i> , 2006, 23, 604-613.	1.7	7
66	Delivering Drugs to the Central Nervous System: A Medicinal Chemistry or a Pharmaceutical Technology Issue?. <i>Current Medicinal Chemistry</i> , 2006, 13, 1757-1775.	1.2	48
67	Long-term delivery of superoxide dismutase and catalase entrapped in poly(lactide-co-glycolide) microspheres: In vitro effects on isolated neonatal porcine pancreatic cell clusters. <i>Journal of Controlled Release</i> , 2005, 107, 65-77.	4.8	56
68	Ketoprofen controlled release from composite microcapsules for cell encapsulation: Effect on post-transplant acute inflammation. <i>Journal of Controlled Release</i> , 2005, 107, 395-407.	4.8	83
69	Plasticizing effect of water on poly(lactide-co-glycolide). <i>Journal of Controlled Release</i> , 2005, 108, 1-9.	4.8	245
70	Novel mucoadhesive buccal formulation containing metronidazole for the treatment of periodontal disease. <i>Journal of Controlled Release</i> , 2004, 95, 521-533.	4.8	153
71	Biodegradable microspheres as carriers for native superoxide dismutase and catalase delivery. <i>AAPS PharmSciTech</i> , 2004, 5, 1-9.	1.5	66
72	Leucinoastatin-A loaded nanospheres: characterization and in vivo toxicity and efficacy evaluation. <i>International Journal of Pharmaceutics</i> , 2004, 275, 61-72.	2.6	25

#	ARTICLE	IF	CITATIONS
73	Unilamellar vesicles as potential capreomycin sulfate carriers: Preparation and physicochemical characterization. AAPS PharmSciTech, 2003, 4, 549-560.	1.5	22
74	Multicellular Tumor Spheroids in Nanomedicine Research: A Perspective. Frontiers in Medical Technology, 0, 4, .	1.3	12